- Home
- COF vs SNY Comparison
COF vs SNY Comparison
Compare COF & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | COF | SNY |
|---|---|---|
| Founded | 1988 | 1994 |
| Country | United States | France |
| Employees | 76300 | 74846 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.6B | 107.3B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | COF | SNY |
|---|---|---|
| Price | $192.75 | $46.76 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 5 |
| Target Price | ★ $263.25 | $58.00 |
| AVG Volume (30 Days) | ★ 4.4M | 3.1M |
| Earning Date | 04-21-2026 | 04-23-2026 |
| Dividend Yield | 1.64% | ★ 3.40% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $96.13 | $3.86 |
| Revenue Next Year | $4.95 | $5.64 |
| P/E Ratio | $52.03 | ★ $6.14 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $157.89 | $43.32 |
| 52 Week High | $259.64 | $55.73 |
Technical Indicators
Market Signals| Indicator | COF | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 54.99 | 52.57 |
| Support Level | $187.50 | $45.20 |
| Resistance Level | $225.94 | $48.88 |
| Average True Range (ATR) | 4.59 | 0.73 |
| MACD | 2.58 | 0.13 |
| Stochastic Oscillator | 85.11 | 58.81 |
Price Performance
Historical ComparisonAbout COF Capital One Financial Corporation
Capital One is a diversified financial services holding company headquartered in McLean, Virginia. Originally a spinoff of Signet Financial's credit card division in 1994, the company is now primarily involved in credit card lending, auto loans, and commercial lending. Following the acquisition of Discover in 2025, the firm also has a modest personal loan business, though credit card lending provides the majority of the bank's revenue.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.